BR0115150A - Radiofarmacêuticos para diagnosticar doença de alzheimer - Google Patents

Radiofarmacêuticos para diagnosticar doença de alzheimer

Info

Publication number
BR0115150A
BR0115150A BR0115150-9A BR0115150A BR0115150A BR 0115150 A BR0115150 A BR 0115150A BR 0115150 A BR0115150 A BR 0115150A BR 0115150 A BR0115150 A BR 0115150A
Authority
BR
Brazil
Prior art keywords
radiopharmaceuticals
disease
alzheimer
diagnose alzheimer
present
Prior art date
Application number
BR0115150-9A
Other languages
English (en)
Inventor
Christoph-Stephan Hilger
Bernd Johannsen
Joerg Steinbach
Peter Maeding
Meredith Halks-Miller
Richard Horuk
Harald Dinter
Raju Mohan
Joseph E Hesselgesser
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0115150A publication Critical patent/BR0115150A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"RADIOFARMACêUTICOS PARA DIAGNOSTICAR DOENçA DE ALZHEIMER". A presente invenção refere-se ao uso de radiofarmacêuticos da fórmula (1) no diagnóstico da doença de Alzheimer. Particularmente, os radiofarmacêuticos da invenção são capazes de passar através da barreira hematoencefálica e ligarem-se ao receptor CCR1 presente no tecido cerebral de pacientes tendo doença de Alzheimer.
BR0115150-9A 2000-11-06 2001-11-01 Radiofarmacêuticos para diagnosticar doença de alzheimer BR0115150A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24629900P 2000-11-06 2000-11-06
PCT/EP2001/012607 WO2002036581A1 (en) 2000-11-06 2001-11-01 Radiopharmaceuticals for diagnosing alzheimer's disease

Publications (1)

Publication Number Publication Date
BR0115150A true BR0115150A (pt) 2003-12-30

Family

ID=22930075

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115150-9A BR0115150A (pt) 2000-11-06 2001-11-01 Radiofarmacêuticos para diagnosticar doença de alzheimer

Country Status (29)

Country Link
US (2) US6676926B2 (pt)
EP (1) EP1332138B1 (pt)
JP (1) JP4234425B2 (pt)
KR (1) KR20030045167A (pt)
CN (1) CN1473158A (pt)
AR (1) AR035366A1 (pt)
AT (1) ATE314354T1 (pt)
AU (2) AU2002214034B2 (pt)
BG (1) BG107762A (pt)
BR (1) BR0115150A (pt)
CA (1) CA2424598A1 (pt)
DE (1) DE60116365T2 (pt)
EA (1) EA006199B1 (pt)
EE (1) EE200300216A (pt)
HR (1) HRP20030459A2 (pt)
HU (1) HUP0301710A3 (pt)
IL (1) IL155191A0 (pt)
JO (1) JO2207B1 (pt)
MX (1) MXPA03003759A (pt)
NO (1) NO20032007L (pt)
NZ (1) NZ525303A (pt)
PE (1) PE20020531A1 (pt)
PL (1) PL361631A1 (pt)
SK (1) SK287495B6 (pt)
TW (1) TWI238820B (pt)
UY (1) UY27003A1 (pt)
WO (1) WO2002036581A1 (pt)
YU (1) YU33203A (pt)
ZA (1) ZA200304409B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
ES2337241T3 (es) 2001-10-22 2010-04-22 Pfizer Products Inc. Derivados de piperazina con actividad antagonista de receptores ccr1.
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ES2421511T3 (es) 2001-12-21 2013-09-03 X Ceptor Therapeutics Inc Moduladores de LXR
DK1620373T3 (da) * 2003-05-07 2008-07-28 Bayer Schering Pharma Ag Apparat og fremgangsmåde til nucleofil fluorering
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
WO2005082425A1 (en) * 2004-02-24 2005-09-09 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR100778888B1 (ko) * 2005-11-29 2007-11-28 재단법인서울대학교산학협력재단 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물
JP2010502719A (ja) 2006-09-08 2010-01-28 ロード アイランド ホスピタル アルコール誘発性脳疾患の治療、予防および回復
AU2007292874B2 (en) 2006-09-08 2013-11-21 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
EP2094625A1 (en) * 2006-12-21 2009-09-02 Hammersmith Imanet, Ltd Radiolabelling methods
WO2009058851A2 (en) * 2007-10-31 2009-05-07 Alseres Pharmaceuticals, Inc. Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
US8450466B2 (en) 2008-03-21 2013-05-28 The General Hosptial Corporation Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
EP2161256A1 (en) * 2008-09-08 2010-03-10 Atomic Energy Council - Institute of Nuclear Energy Research Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof
EP2163541A1 (en) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
WO2011041470A2 (en) * 2009-09-30 2011-04-07 Mallinckrodt Inc. Sustained-release opiate and opiate derivative compositions
TW201201846A (en) * 2010-02-08 2012-01-16 Bayer Schering Pharma Ag Iodo precursor for a PET imaging agent of amyloid plaques
WO2011110511A1 (en) * 2010-03-11 2011-09-15 Bayer Pharma Aktiengesellschaft Spect imaging agents of amyloid plaques
US9572787B2 (en) 2011-05-19 2017-02-21 Rhode Island Hospital Inhibition of renal fibrosis
JP6584322B2 (ja) 2013-12-27 2019-10-02 国立大学法人 東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
DK3340796T3 (da) * 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576611A4 (en) * 1991-03-13 1996-01-24 Univ Minnesota Radiopharmaceutical agents for the detection of alzheimer's disease
EP0524146A1 (de) 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
GB9413772D0 (en) 1994-07-08 1994-08-24 Wyeth John & Brother Ltd 5-HT1A ligands
AU2680797A (en) * 1996-04-24 1997-11-12 Emory University Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites
WO1998002151A2 (en) 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
TR200102800T2 (tr) 1999-03-26 2002-01-21 Astrazeneca Ab Yeni bileşikler.
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer

Also Published As

Publication number Publication date
HUP0301710A3 (en) 2007-03-28
PL361631A1 (en) 2004-10-04
DE60116365T2 (de) 2006-08-24
IL155191A0 (en) 2003-11-23
CN1473158A (zh) 2004-02-04
BG107762A (en) 2004-03-31
AR035366A1 (es) 2004-05-12
HUP0301710A2 (hu) 2003-11-28
SK5472003A3 (en) 2003-10-07
JP4234425B2 (ja) 2009-03-04
US6676926B2 (en) 2004-01-13
EP1332138A1 (en) 2003-08-06
PE20020531A1 (es) 2002-06-15
EA006199B1 (ru) 2005-10-27
WO2002036581A1 (en) 2002-05-10
SK287495B6 (sk) 2010-12-07
MXPA03003759A (es) 2003-07-28
EP1332138B1 (en) 2005-12-28
NZ525303A (en) 2004-10-29
ZA200304409B (en) 2004-09-06
US6872381B1 (en) 2005-03-29
YU33203A (sh) 2006-05-25
HRP20030459A2 (en) 2005-04-30
JO2207B1 (en) 2004-10-07
KR20030045167A (ko) 2003-06-09
DE60116365D1 (de) 2006-02-02
AU2002214034B2 (en) 2006-01-05
NO20032007D0 (no) 2003-05-05
ATE314354T1 (de) 2006-01-15
EE200300216A (et) 2003-08-15
AU1403402A (en) 2002-05-15
JP2004513123A (ja) 2004-04-30
EA200300507A1 (ru) 2003-12-25
US20020131932A1 (en) 2002-09-19
NO20032007L (no) 2003-07-02
TWI238820B (en) 2005-09-01
UY27003A1 (es) 2002-07-31
CA2424598A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
BR0115150A (pt) Radiofarmacêuticos para diagnosticar doença de alzheimer
BR0110748A (pt) Plataforma de nanodispositivo multifuncional
HUP0100159A2 (hu) Az Alzheimer-kór életben történő diagnosztizálására és amiloidlerakódás in vivo kimutatására és megelőzésére alkalmas vegyületek
DK1334091T3 (da) Thioflavinderivater og deres anvendelse til diagnose og terapi af Alzheimer's sygdom
AU3891499A (en) Diagnostic tests for alzheimer's disease
ATE268187T1 (de) Bioaktivierte diagnostische bilderzeugungskontrastmittel
TR200001795T2 (tr) 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı.
MA30252B1 (fr) Vaccin therapeutique
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
HK1087394A1 (en) Methods of 11c radiolabelling phenothiazine and pheno thiazine-like compounds
IT8920168A0 (it) Composizione farmaceutica per uso orale adatta all'impiego nel lavaggio gastro intestinale, in particolare per uso diagnostico, oppure come lassativo catartico.
BRPI0408295A (pt) uso de um composto
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
IL175004A0 (en) Quick test for the diagnosis of alzheimer's disease
CL2004001068A1 (es) Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer.
DE60207612D1 (de) Verbindungen zur bilddarstellung der alzheimer-krankenheit
BR9810215A (pt) Dispositivos para a mamografia de projeção
BR0110512A (pt) Preparação para medir a taxa de esvaziamento gástrico
KR960028907A (ko) 암환자를 치료하기 위한 세트랄린의 용도
PT1251875E (pt) Uttlizacao de agentes de contraste na preparacao de um agente de diagnostico para a visualizacao do lumen intestinal
HUP0004667A2 (hu) Új, optikailag aktív aminopentán-származékok
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
ITFI20020176A1 (it) Immunoglobulina specifica per callicreina tessutale umana, formulazione immunologica comprendente detta immunoglobulina e relativo kit diagnostico per la diagnosi dell'ischemia cerebrale.
JP2004530642A5 (pt)
FR2766927B1 (fr) Methodes et kits pour le diagnostic de la maladie d'alzheimer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 1964 DE 26/08/2008 E CONSIDERANDO A AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS.